tradingkey.logo

AGMB.NB

AGMB
10.850USD
-1.020-8.59%
收盤 03/27, 16:00美東報價延遲15分鐘
528.79M總市值
虧損本益比TTM

AGMB.NB

10.850
-1.020-8.59%

關於 AGMB.NB 公司

Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

AGMB.NB簡介

公司代碼AGMB
公司名稱Agomab Therapeutics NV
上市日期Feb 06, 2026
CEOKnotnerus (Tim)
員工數量- -
證券類型Depository Receipt
年結日Feb 06
公司地址Posthoflei 1/6
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Belgium
郵編2600
電話
網址https://agomab.com/
公司代碼AGMB
上市日期Feb 06, 2026
CEOKnotnerus (Tim)

AGMB.NB公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--
Mr. Pierre Kemula
Mr. Pierre Kemula
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David R. Epstein
Mr. David R. Epstein
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Angelika Jahreis
Ms. Angelika Jahreis
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Colin Bond
Mr. Colin Bond
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Tim Knotnerus
Mr. Tim Knotnerus
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
10.82K
--
,
,
--
--
Mrs. Ellen Lefever
Mrs. Ellen Lefever
General Counsel
General Counsel
--
--
Dr. Paul van der Horst
Dr. Paul van der Horst
Chief Business Officer
Chief Business Officer
--
--
Dr. Philippe Wiesel
Dr. Philippe Wiesel
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrea Saez
Dr. Andrea Saez
Chief Development Officer
Chief Development Officer
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 3月17日 週二
更新時間: 3月17日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.90%
EQT Life Sciences
2.29%
Knotnerus (Tim)
0.02%
其他
87.79%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
9.90%
EQT Life Sciences
2.29%
Knotnerus (Tim)
0.02%
其他
87.79%
股東類型
持股股東
佔比
Investment Advisor
9.90%
Venture Capital
2.29%
Individual Investor
0.02%
其他
87.79%

機構持股

由於公司未披露,未能獲取相關數據
報告期間
機構數
持股數
持股佔比
持股變動
暫無數據

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
暫無數據
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
KeyAI